Does semaglutide slow aging?

Why people ask whether semaglutide affects aging

FDA has approved specific semaglutide products only for specific uses, which differ by product, and has not approved any semaglutide product for anti-aging or longevity (checked September 27, 2026). Researchers are studying whether semaglutide affects aging, and in searches of PubMed, Europe PMC and ClinicalTrials.gov on October 1, 2026, the human results we found were analyses of lab markers of biological age (the peer-reviewed ones post hoc), which do not show how long or how well people live.[1][2]

In searches of ClinicalTrials.gov, PubMed and Europe PMC on October 1, 2026, we found three registered randomized trials that include semaglutide and whose registry record or published protocol names markers of aging among the primary outcomes.[3][4][5][6] All three are small: one plans 66 adults with obesity, one plans 30 postmenopausal women aged 46 to 60 with obesity, and one, now complete, enrolled 20 adults aged 65 or older with prediabetes or type 2 diabetes.[3][4][5] All three trials are registered; none has reported results for its aging markers in ClinicalTrials.gov, PubMed or Europe PMC as of October 1, 2026, and the one completed trial has posted a single result, a change in lean body mass.[5]

In a ClinicalTrials.gov search on October 1, 2026, we also found one registered randomized trial that compares low-dose semaglutide with placebo in adults aged 18 to 65 enrolled as healthy volunteers; it plans 150 participants, and the registry lists an industry sponsor.[7] That trial is registered; it has reported no results in ClinicalTrials.gov, PubMed or Europe PMC as of October 1, 2026, and its registered outcomes are pain, mood, sleep, physical activity, heart rate variability and routine blood tests, with no death or lifespan outcome.[7]

Biological-age markers in two small analyses

FDA has approved specific semaglutide products only for specific uses, which differ by product, and has not approved any semaglutide product for anti-aging or longevity (checked September 27, 2026). One small trial of semaglutide in 84 adults with HIV-related fat buildup later analyzed blood markers called epigenetic clocks, and reported lower biological-age scores with semaglutide than with placebo after 32 weeks.[1] The epigenetic-clock analysis of semaglutide in adults with HIV was not planned when the trial began, was small and lasted only 32 weeks, and its authors said these limits restrict how widely the results apply.[1]

A separate analysis, also done after the study was designed, looked at 41 adults with HIV and fatty liver disease who all took semaglutide 1 mg weekly for 24 weeks.[2] Fewer than half of them (41.5%) had a lower score at the end on an epigenetic clock that estimates the pace of aging, and the study had no comparison group, so it cannot show what semaglutide itself changed.[2] According to the paper, that analysis was funded by the U.S. National Institutes of Health, with added support from a university medical school and a charitable trust.[2] Epigenetic clocks estimate biological age from chemical marks on DNA in blood, and a lower clock score is a lab marker, not proof of a longer or healthier life.

Heart events and deaths in trials of people with existing disease

FDA has approved specific semaglutide products only for specific uses, which differ by product, and has not approved any semaglutide product for anti-aging or longevity (checked September 27, 2026). In the SELECT trial, which was funded by semaglutide's maker, adults aged 45 or older with existing cardiovascular disease and overweight or obesity, but without diabetes, who took semaglutide 2.4 mg once weekly had about a 20% lower risk of a first heart attack, stroke or cardiovascular death, counted together, than those on placebo: 6.5% vs 8% of people had one of these events.[8][9] In SELECT, a heart attack, stroke or cardiovascular death occurred in 6.5% of people taking semaglutide and 8.0% of people on placebo over an average follow-up of about 3.3 years.[8] SELECT enrolled only people who already had cardiovascular disease, so its results do not show a heart or survival benefit for people without it.

In the SELECT trial, which was funded by semaglutide's maker, 17,604 adults aged 45 or older with overweight or obesity and existing cardiovascular disease, but without diabetes, were randomly assigned to once-weekly semaglutide 2.4 mg or placebo, and death from any cause was the third of three secondary outcomes that the trial planned to test in a fixed order.[8] According to the SELECT paper, the first of the three, death from cardiovascular causes, did not reach the statistical threshold the trial required, so the other two, including death from any cause, were not formally tested.[8] The SELECT paper reports deaths from any cause in 375 of 8,803 people assigned to semaglutide (4.3%) and 458 of 8,801 assigned to placebo (5.2%), a hazard ratio of 0.81 (95% confidence interval 0.71 to 0.93), and says this interval, which was not adjusted for testing several outcomes, should not be used to infer a definite treatment effect.[8] The Wegovy prescribing information gives the same figures and says the result for death from any cause was not statistically significant under the trial's planned testing order.[10]

A 2026 review of 262 obesity-drug trials found that injected semaglutide was linked to fewer deaths from any cause, an estimate the authors said came mainly from heart trials in high-risk people.[11]

In the FLOW trial, which was funded by semaglutide's maker, 3,533 adults with type 2 diabetes and chronic kidney disease were randomly assigned to once-weekly semaglutide 1.0 mg (an Ozempic injection dose, not the 2.4 mg dose used for weight management) or placebo, and the risk of death from any cause, a secondary outcome, was 20% lower with semaglutide than with placebo (hazard ratio 0.80, 95% confidence interval 0.67 to 0.95).[12] FLOW enrolled only people with type 2 diabetes and chronic kidney disease, so its result does not show a survival benefit for people without those conditions. FLOW was designed to test kidney outcomes and was stopped early at a planned interim analysis, after a median follow-up of 3.4 years.[12]

In searches of PubMed, Europe PMC and ClinicalTrials.gov on October 1, 2026, we found no randomized trial that tested whether semaglutide lowers the risk of death or extends lifespan in people without a diagnosed condition. As of October 1, 2026, our ClinicalTrials.gov search found 19 registered randomized trials involving semaglutide that list death from any cause or time to death among their outcomes, and each is limited to people with a named condition, such as type 2 diabetes, cardiovascular disease, heart failure or chronic kidney disease. Six of those 19 trials list overweight or obesity among their conditions, and each of the six also requires another condition, such as existing cardiovascular disease, heart failure or atrial fibrillation.

The FDA status table lists Ozempic injection with the uses in its prescribing information.

According to the Wegovy prescribing information, a benefit of semaglutide on cardiovascular death by itself was not confirmed in SELECT.[10] The Wegovy prescribing information says the exact way semaglutide lowers cardiovascular risk in adults has not been established.[9]

The same 2026 review of 262 trials found that no obesity drug, including semaglutide, improved quality of life by an amount considered meaningful.[11]

Sources: Wegovy injection prescribing information, Revised 06/2026.

Brain health and Alzheimer's disease

In two large trials, evoke and evoke+, oral semaglutide did not slow early Alzheimer's disease.[13] The evoke and evoke+ trials included 3,808 people aged 55 to 85 with early Alzheimer's disease confirmed by amyloid testing, who took oral semaglutide up to 14 mg daily or placebo.[13] In evoke and evoke+, the change in dementia rating scores after 2 years was essentially the same with semaglutide as with placebo.[13]

Semaglutide is not FDA-approved for Alzheimer's disease. FDA has approved specific semaglutide products only for specific uses: Ozempic injection, Ozempic tablets and Rybelsus tablets for uses in adults with type 2 diabetes, and Wegovy injection and Wegovy tablets for lowering cardiovascular risk in adults with established cardiovascular disease and obesity or overweight, and for weight management in certain people (plus, for Wegovy injection only, MASH under accelerated approval). Using semaglutide for Alzheimer's disease is off-label. FDA has not reviewed whether it is safe and effective for that purpose.

In searches of PubMed, Europe PMC and ClinicalTrials.gov on October 1, 2026, we found no randomized trial with reported results that was designed to test whether semaglutide prevents dementia in people who do not have it. One registered randomized trial, called ISAP, compares oral semaglutide with placebo in up to 88 adults aged 55 or older who have amyloid in the brain and no or mild cognitive impairment, and its main outcome is the one-year change in a brain scan for tau protein.[14] ISAP is registered; in searches of PubMed and Europe PMC on October 1, 2026, we found its protocol and no reported results.[14]

Harms and trade-offs

According to the Wegovy prescribing information, semaglutide lowers body weight with greater fat mass loss than lean mass loss, so some of the weight lost is lean mass, not only fat.[9] Reviews of trials of GLP-1 medicines, including semaglutide, estimated that lean mass made up roughly a quarter to over a third of the total weight lost.[15][16]

In the STEP 1 trial extension, which was funded by semaglutide's maker, people had regained, on average, about two-thirds of the weight they had lost one year after stopping semaglutide.[17]

According to the Wegovy prescribing information, "adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice."[9] In the Wegovy 2.4 mg injection trials, stomach and bowel side effects were reported by 73% of people on Wegovy and 47% of people on placebo.[9] The SELECT trial enrolled 17,604 adults aged 45 or older with existing cardiovascular disease and overweight or obesity, but without diabetes. In SELECT, 16.6% of people taking semaglutide and 8.2% of people on placebo stopped treatment permanently because of side effects.[8]

The Wegovy label carries a boxed warning that semaglutide caused thyroid C-cell tumors in rodents, and that whether semaglutide causes these tumors in humans is unknown because the human relevance of the rodent tumors has not been determined.[9] The Wegovy prescribing information says Wegovy should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC), or with MEN 2, or by people who have had a serious allergic reaction to semaglutide or to any ingredient in Wegovy injection or Wegovy tablets.[9] The Wegovy prescribing information also warns about acute pancreatitis, gallbladder disease, low blood sugar (with a higher risk when taken with insulin or a sulfonylurea), kidney injury from dehydration, severe stomach and bowel reactions, serious allergic reactions, diabetic eye complications in people with type 2 diabetes, a faster heart rate, and inhaling stomach contents during anesthesia or deep sedation.[9]

The Ozempic prescribing information says Ozempic injection should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC), or with MEN 2, or by people who have had a serious allergic reaction to semaglutide or to any ingredient in Ozempic injection.[18] The Ozempic prescribing information also warns about acute pancreatitis, diabetic eye complications, never sharing a pen between patients, low blood sugar when Ozempic injection is used with insulin or with a medicine such as a sulfonylurea, kidney injury from dehydration, severe stomach and bowel reactions, serious allergic reactions, gallbladder disease, and inhaling stomach contents during anesthesia or deep sedation.[18]

The prescribing information for each semaglutide product in the FDA status table carries a boxed warning about the risk of thyroid C-cell tumors.

If you have severe symptoms, call 911 or seek emergency care. Report side effects to FDA MedWatch.

Sources: Wegovy injection prescribing information, Revised 06/2026, Wegovy tablets prescribing information, Revised 06/2026, Ozempic injection prescribing information, Revised 05/2026.

Talk to a licensed clinician about whether any semaglutide product is appropriate for you.

Regulatory status

Semaglutide is not FDA-approved for anti-aging, longevity or general wellness. FDA has approved specific semaglutide products only for specific uses: Ozempic injection, Ozempic tablets and Rybelsus tablets for uses in adults with type 2 diabetes, and Wegovy injection and Wegovy tablets for lowering cardiovascular risk in adults with established cardiovascular disease and obesity or overweight, and for weight management in certain people (plus, for Wegovy injection only, MASH under accelerated approval). Using semaglutide for anti-aging or longevity is off-label. FDA has not reviewed whether it is safe and effective for that purpose.

FDA's shortage and discontinuation data list Rybelsus tablets as 'To Be Discontinued' (posted June 4, 2026).

The FDA status table lists the Wegovy products and Ozempic injection named on this page with the uses in their prescribing information.

Each semaglutide product in the FDA status table is available only with a prescription (checked September 27, 2026).

Regulatory status checked September 27, 2026. Sources: www.accessdata.fda.gov/…/209637s038lbl.pdf; www.accessdata.fda.gov/…/213051Orig1s030lbl.pdf; www.accessdata.fda.gov/…/215256s025lbl.pdf; www.fda.gov/…/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize; public-inspection.federalregister.gov/…/2026-12937.pdf; www.fda.gov/…/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list; www.fda.gov/…/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss; www.fda.gov/…/compounding-and-fda-questions-and-answers; www.accessdata.fda.gov/…/218316Orig1s000ltr.pdf; www.accessdata.fda.gov/…/218316s007lbl.pdf

Related pages

• Semaglutide for Weight Loss
• Is Semaglutide FDA-Approved for Weight Loss?